- (S)-Thalidomide
-
- $56.00 / 5mg
-
2026-03-13
- CAS:841-67-8
- Min. Order:
- Purity: 99.89%
- Supply Ability: 10g
- (S)-Thalidomide
-
- $56.00 / 5mg
-
2026-03-13
- CAS:841-67-8
- Min. Order:
- Purity: 99.89%
- Supply Ability: 10g
- (S)-thalidomide
-
- $0.00 / 25mg
-
2025-06-07
- CAS:841-67-8
- Min. Order: 25mg
- Purity: >99.00%
- Supply Ability: 25mg
|
| | (-)-THALIDOMIDE Basic information |
| Product Name: | (-)-THALIDOMIDE | | Synonyms: | 6-dioxo-3-piperidinyl)-3(2h)-dion(s)-1h-isoindole-2-(2;6-dioxo-3-piperidyl)-n-(l-(-)-phthalimid;(S)-2-(2,6-DIOXO-3-PIPERIDINYL)-1H-ISOINDOLE-1,3-(2H)-DIONE;S(-)-2-(2,6-DIOXO-3-PIPERIDINYL)-1H-ISOINDOLE-1,3(2H)-DIONE;(S)-(-)-THALIDOMIDE;(-)-THALIDOMIDE >98% INHIBITOR OF ANGIOG EN;(-)-N-[(S)-2,6-Dioxo-3-piperidinyl]phthalimide;(3S)-3-(1,3-Dioxo-2H-isoindole-2-yl)piperidine-2,6-dione | | CAS: | 841-67-8 | | MF: | C13H10N2O4 | | MW: | 258.23 | | EINECS: | 635-910-2 | | Product Categories: | Chiral Reagents;Intermediates & Fine Chemicals;Pharmaceuticals | | Mol File: | 841-67-8.mol |  |
| | (-)-THALIDOMIDE Chemical Properties |
| Melting point | 269-271°C | | Boiling point | 401.48°C (rough estimate) | | density | 1.2944 (rough estimate) | | refractive index | 1.5300 (estimate) | | storage temp. | -20°C Freezer | | solubility | DMSO: soluble | | pka | 10.70±0.40(Predicted) | | form | solid | | color | white | | Optical Rotation | [α]23/D 62.6°, c = 2 in DMF(lit.) | | InChI | InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)/t9-/m0/s1 | | InChIKey | UEJJHQNACJXSKW-VIFPVBQESA-N | | SMILES | C1(=O)C2=C(C=CC=C2)C(=O)N1[C@H]1CCC(=O)NC1=O |
| Hazard Codes | T | | Risk Statements | 61-22 | | Safety Statements | 53-36/37/39-45 | | RIDADR | UN 2811 6.1/PG 2 | | WGK Germany | 3 | | RTECS | TI4925050 | | Storage Class | 6.1C - Combustible acute toxic Cat.3
toxic compounds or compounds which causing chronic effects | | Hazard Classifications | Acute Tox. 4 Oral
Repr. 1B |
| | (-)-THALIDOMIDE Usage And Synthesis |
| Chemical Properties | Needles | | Uses | Optically active isomer of Thalidomide, which inhibits FGF-induced angiogenesis. Inhibits replication of human immunodeficiency virus type 1. Teratogenic sedative | | Uses | Thalidomide has been used to study its teratogenic effects in chicken embryos and human embryonic cells. This study reported that thalidomide causes limb defects by stabilizing PTEN, inhibiting the expression of Akt and activating caspase-dependent apoptosis. Thalidomide has also been used for studying glutathione mediated teratogenic resistance in mouse embryos. | | Definition | ChEBI: A 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione that has S-configuration at the chiral centre. | | General Description | Thalidomide is a stereoisomer, which exists in two enantiomeric states. The S enantiomer is teratogenic. Thalidomide consists of two linked rings, a phthalimide and glutarimide ring. | | reaction suitability | reagent type: ligand | | Biochem/physiol Actions | (-)-Thalidomide selectively inhibits the biosynthesis of tumor necrosis factor α (TNF-α), which is essential for inflammatory response. It is an anti-emetic drug and is used to treat morning sickness in pregnant women. Thalidomide is also used to treat leprosy, multiple myeloma, Crohn′s disease and human immunodeficiency virus (HIV) infection. Thalidomide also inhibits angiogenesis. It is associated with several diseases such as, peripheral neuropathy, facial palsies, Duane syndrome and autism. |
| | (-)-THALIDOMIDE Preparation Products And Raw materials |
|